Business Wire

Wound Care: Nexodyn® AOS Comes to Fruition in Slovakia

Share

Nexodyn® AcidOxidizing Solution (AOS), the Tehclo-based product for acute and chronic wound management, is now available in Slovakia, promoted and commercialized by the pharmaceutical companies Evopharm and Sanomed, pursuant to an exclusive partnership with the Swiss pharma company APR Applied Pharma Research s.a. (“APR”).

After Slovakia, in early 2019 Evopharm will expand the distribution of the product first to Poland, where the registration is currently being completed, and then to Czech Republic.

As confirmed by the results of pre-launch activities, Evopharm is confident that Nexodyn® AOS, based on APR’s proprietary and patented technology Tehclo®, can offer to Slovak Healthcare Professionals (“HCPs”) and caregivers a new treatment option to effectively address the wound healing complexity.

Local KOLs, involved in an Advisory Board, got particularly impressed from the distinctive physico-chemical properties of this product, able to create the ideal microenvironment to sustain the physiological healing process of wounds; clinical evidences have shown Nexodyn® AOS to promote the restart of wound healing, which is considered of great value.

Another benefit of Nexodyn® AOS in interviewed HCPs’ eyes is the local ancillary antimicrobial effect on the wound surface, due to the highly pure and stabilized hypochlorous acid, which can help prevent contamination or contribute to counteract local infections.

“We are very proud about our collaboration with APR and to have the chance to provide Slovak HCPs’ dealing with acute and chronic wounds of such a powerful product. We believe that Nexodyn® AOS, being the first wound cleanser on the Slovak market containing hypochlorous acid, could really make a difference in the treatment of diabetic foot ulcers, lower leg ulcers and pressure ulcers.” commented Martin Hustaty, CEO of Evopharm together with Aneta Manova, CEO of Sanomed.

Sanomed will support the distribution and the promotion of Nexodyn® AOS with a consistent range of activities addressing the HCPs at different levels, from KOLs to hospitals, as well as pharmacists and nurses, like congresses, training courses and e-mailing campaigns, with the purpose of establishing Nexodyn® AOS as the first wound cleanser restarting the physiological healing process of wounds.

”We are very pleased to see Nexodyn® AOS available on Slovak market. This launch comes after previous marketing of the product in Italy, US, Saudi Arabia and UAE, as a result of several partnerships with leading pharmaceutical companies.” said Paolo Galfetti, Chief Executive Officer of APR. “Other markets will follow in the next year confirming Nexodyn® AOS appeal and efficacy among the available wound care solutions”.

About Nexodyn® AcidOxidizing Solution (AOS)

Nexodyn® AcidOxidizing Solution (AOS) is a sprayable Active Cleanser with an ancillary antimicrobial activity developed for acute and chronic wound management.

A wide array of clinical experiences and studies demonstrated Nexodyn® to be a unique Wound healing Restarter by creating the ideal microenvironment to sustain the physiological healing process. Restarting wound healing, favoring an optimized lesion closure and ensuring a favorable safety and tolerability profile, is especially relevant with chronic wounds.

Developed based on APR’s proprietary and patented technology Tehclo®, the product is a newly conceived solution with three main features: highly pure and stabilized hypochlorous acid (HClO >95% of free chlorine species), acidic pH (2.5 – 3.0) and high Reduction-Oxidation Potential (ORP >1.000 mV).

Nexodyn® AcidOxidizing Solution (AOS) is intended for use in the debridement, irrigation, cleansing and moistening of acute and chronic wounds (e.g. diabetic foot ulcers, pressure ulcers, and vascular ulcers), post-surgical wounds, burns and other lesions.

As observed in non-clinical experiments and clinical experiences, Nexodyn® AcidOxidizing Solution (AOS) has synergic physico-chemical properties sustaining the restart of wound healing to the benefit of patients and HCPs who can be confident of the reactivation of the physiological healing process concomitantly to protection and management of uncontrolled microbial growth. Nexodyn® AcidOxidizing Solution (AOS) shows favorable safety and tolerability profile and the clinical experiences performed confirm its high relief sensation and comfort at application as well as wound-associated pain reduction.

For more info, please visit: http://www.apr.ch/apr-pharma-products/medical-prescription/nexodyn-wound-healing/

About APR Applied Pharma Research s.a.

APR is a Swiss independent pharma company focused on development and commercialization of innovative, science-driven products designed to address unmet needs in niche or rare therapeutic areas on a global basis.

APR combines drug development expertise with proprietary drug delivery technologies to deliver to patients suffering from rare diseases with solutions meaningfully improving their life and empowering caregivers with better ways to manage such rare diseases.

APR has a balanced portfolio of revenue generating products marketed in all major markets, combined with a compelling pipeline of innovative products at different stages of development, specifically in the treatment of rare recessive metabolic disorders, rare dermatological and ocular diseases.

APR’s products are commercialized by APR directly through its own sale and marketing teams in selected countries of Europe as well as through a solid global network of commercial partners.

About Evopharm and/or Sanomed

Since 2010 Evopharm brings a high quality, safe and affordable medicines to the market. Our mission is to provide effective solutions for our patients and help them to live a full and happy life. Our commitment to deliver a high quality and professional service is characterized by the status of a rapidly evolving institution. Complex care management in the field of medicines is realized in Central and Eastern Europe and in selected Asian countries. We naturally pay an attention to the ethical, social and environmental dimensions in our every action and decision.

SANOMED is a dinamically-evolving pharmaceutical company operating in Central and Eastern Europe, contributing a large medicine portfólio to the market since 2011. We provide our business partners with a complex package of services from introductory works, registration, launching of the product to its selling and gaining the expected market share. Our effective and safe medicine from many therapeutic fields returns hopes of a full life to people. We strive to improve patient´s health and quality of life and to be a reliable partner to our clients and associates working in healthcare and pharmaceutical industries.

„We´re doing our best to be beneficial to patients and our healthcare partners alike”.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

APR Applied Pharma Research s.a.:
Elisabetta Bianchi, Corporate Communication Manager
T +41 91 6957020 or e-mail to: elisabetta.bianchi@apr.ch
or
SANOMED s.r.o.
Silvia Matliakova, Product Manager
e-mail to: silvia.matliakova@sanomed.sk

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NIKE, Inc. Board of Directors Announces Long-Time Nike Veteran Elliott Hill to Return as President and Chief Executive Officer John Donahoe to Retire from Nike19.9.2024 23:15:00 EEST | Press release

The Board of Directors of NIKE, Inc. (NYSE:NKE) announced today that Elliott Hill will become President and Chief Executive Officer of NIKE, Inc., effective October 14, 2024. Hill will also become a Director of the NIKE, Inc. Board of Directors and a member of the Executive Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240919388699/en/ Incoming NIKE, Inc. President & CEO Elliott Hill (Photo: Business Wire) “I am excited to welcome Elliott back to NIKE. Given our needs for the future, the past performance of the business, and after conducting a thoughtful succession process, the Board concluded it was clear Elliott’s global expertise, leadership style, and deep understanding of our industry and partners, paired with his passion for sport, our brands, products, consumers, athletes, and employees, make him the right person to lead Nike’s next stage of growth,” said Mark Parker, Executive Chairman of NIKE, Inc. “Pers

Mary Kay Expands Into Kyrgyzstan, Further Elevating Beauty and Empowerment Around the World19.9.2024 20:03:00 EEST | Press release

Mary Kay Inc., a global leader in skin care and cosmetics, is proud to announce its expansion into Kyrgyzstan, marking a significant milestone in its ongoing international growth strategy. This exciting development underscores Mary Kay’s commitment to empowering women and providing innovative, high-quality skincare and beauty products across the globe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240919159057/en/ Mary Kay’s expansion into Kyrgyzstan marks another step forward in the company’s mission to enrich women’s lives around the world, offering top-tier beauty products and unparalleled business opportunities. (Photo: Mary Kay Inc.) The beauty and personal care market is experiencing robust growth internationally, with sales volume in these categories almost doubling over the past several years. The beauty market is expected to reach approximately $580 billion by 2027, growing by a projected 6 percent per year1 while

Xsolla Partners With AbleGamers for Charity Campaign at TwitchCon 202419.9.2024 20:00:00 EEST | Press release

Xsolla, a global video game commerce company, is excited to announce its collaboration with AbleGamers for an impactful charity campaign at TwitchCon 2024. This partnership aims to further AbleGamers' mission of improving accessibility in gaming for individuals with disabilities through an interactive and meaningful activation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240919722398/en/ (Graphic: Xsolla) Attendees who visit the Xsolla booth (Booth 1515-SW) at TwitchCon will have the exclusive opportunity to claim one of two specially designed charity pins. By sharing a photo of their pin on their social channels on Instagram, Facebook, or Twitter using the hashtags #LightstreamAble and #XsollaAble, participants will help raise funds for AbleGamers. For every qualifying social post, Xsolla and its partners will donate $5 to AbleGamers, up to $10,000. To amplify awareness, include hashtags: #TwitchCon #BongoCat #Lightstrea

Sandvine Announces New Ownership and Capital Infusion19.9.2024 19:38:00 EEST | Press release

Sandvine (the “Company”), a market-leading provider of Over-the-Top (OTT) Application Classification and Quality of Experience (QoE) solutions, today announced that it has been acquired by a group of leading US investment firms that previously were, and continue to be, lenders to the Company. In connection with this change of control transaction, the lenders agreed to reduce the Company’s total outstanding debt significantly. Following the change of control transaction, on September 13, 2024, these investors also entered into a binding agreement to provide new capital to Sandvine. The financing is expected to close in September 2024 and will strengthen the Company’s balance sheet. These enhancements to Sandvine’s financial position accompany its recently announced reorientation of its business model to focus on serving customers in large democratic markets. Together, these developments enable the Company to continue serving as the technology partner of choice for scaled, sophisticated

Neuraptive Therapeutics Announces Presentation of Phase 2 Topline Interim Results for NTX-001 at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting19.9.2024 19:31:00 EEST | Press release

Neuraptive Therapeutics Inc., a leading biopharmaceutical company focused on novel treatments for peripheral nerve injuries, today announced that interim topline results from its ongoing Phase 2 NEUROFUSE Study will be presented at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting, held September 19-21 in Minneapolis, MN. The presentation, titled Safety and Efficacy of NTX-001 in the Treatment of Acute Single Transected Peripheral Nerve Injuries: A Phase 2 Randomized Controlled Trial, was awarded a Top 10 Best Paper designation and will be presented by Dr. David Brogan of Washington University during the scientific paper session on Thursday, September 19. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240919597699/en/ David M. Brogan, MD, MSc, Assistant Professor, Orthopaedic Surgery, Division of Hand and Microsurgery, Washington University in St. Louis (Photo: Business Wire) The presentation will highl

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye